This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager.
Dismiss

Seqirus succeeds in opposing Moderna's patent for mRNA vaccine in Australia

By Saloni Sinha ( July 17, 2025, 07:46 GMT | Insight) -- Global influenza vaccine company Seqirus’ opposition to US pharma giant Moderna’s patent application over a method for producing high-purity mRNA suitable for use in vaccines has been accepted by a delegate of Australia’s patent office. In a ruling published recently, delegate M. Umehara of the Australian Patent Office accepted Seqirus’ opposition based on the absence of an “inventive step.” Seqirus claimed that Moderna was merely applying well-known scientific principles. Global influenza vaccine company Seqirus’ opposition to US pharma giant Moderna’s patent application over a method for producing high-purity mRNA suitable for use in vaccines has been accepted by a delegate of Australia’s patent office....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login